

## Instructions for Authors 2016

*General Policy.* ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

*NIH Open Access Policy.* The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

*Copyright.* Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

*Format.* Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

*Manuscripts.* Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Acknowledgements*; (h) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

*Figures.* All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges.

*Tables.* All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

*References.* Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

*Nomenclature and Abbreviations.* Nomenclature should follow that given in "Chemical Abstracts", "Index Medicus", "Merck Index", "IUPAC –IUB", "Bergey's Manual of Determinative Bacteriology", The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

*Clinical Trials.* Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

*Ethical Policies and Standards.* ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 ([www.icmje.org](http://www.icmje.org)). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

*Submission of Manuscripts.* Please follow the Instructions for Authors regarding the format of your manuscript and references.

Manuscripts must be submitted only through our online submission system at: <http://www.iiar-submissions.com/login.html>

In case a submission is incomplete, the corresponding Author will be notified accordingly.

Questions regarding difficulties in using the online submission system should be addressed to: email: [journals@iiar-anticancer.org](mailto:journals@iiar-anticancer.org)

*Galley Proofs.* Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles published in 2015 are entitled to a complimentary online subscription to Anticancer Research 2015. Requests should be addressed to the Editorial Office. Galley proofs should be returned corrected to the Editorial Office by email within two days.

Copyright© 2016 - International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

### ***Specific information and additional instructions for Authors***

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.
2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees. (For further information please click [here](#))
3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.

4. Each manuscript submitted to AR is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal's secretary, the reviewers and the printers.
5. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author's writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.
6. Authors should pay attention to the following points when writing an article for AR:
  - The Instructions to Authors must be followed in every detail.
  - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
  - The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
  - Results given in figures should not be repeated in tables.
  - Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
  - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
  - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
  - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
  - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
  - The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
  - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.
7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.
8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).
9. Articles submitted to AR may be rejected without review if:
  - they do not fall within the journal's policy.
  - they do not follow the instructions to authors.
  - language is unclear.
  - results are not sufficient to support a final conclusion.
  - results are not objectively based on valid experiments.
  - they repeat results already published by the same or other authors before the submission to AR.
  - plagiarism is detected by plagiarism screening services.

(Rejection rate (2015): 64%).
10. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.
11. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to [journals@iiar-anticancer.org](mailto:journals@iiar-anticancer.org)
12. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.
13. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service.

(This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).

# INVITATION TO SUBMIT ABSTRACTS

THE BINAYTARA FOUNDATION  
PRESENTS



4<sup>th</sup> International Conference on Advances in Hematology  
and Oncology  
*August 13-14, 2016*

The Coeur d'Alene Resort  
Coeur d'Alene, Idaho, USA.

<http://oncology.binayfoundation.org>

Abstract Submission Deadline: Sunday, June 16th, 2016

Accepted abstracts will be published in the Anticancer Research  
Journal

We will accept abstracts in the following categories:

1. Basic science research
2. Clinical research
3. Case reports



E-mail - [hemeonc@binayfoundation.org](mailto:hemeonc@binayfoundation.org) with any questions.

## Target audience:

Basic science & clinical researchers  
Hematologists/Oncologists, Surgeons, Radiation oncologists  
Internists, Pharmacists, Nurses, and Others

## Why Attend?

Renowned faculties from leading institutions  
Opportunity for 1:1 discussion with faculty  
Audience Response System  
Scientific abstract sessions  
Networking  
Location



Stereotactic Body Radiation Therapy (SBRT) for Recurrent Non-small Cell Lung Cancer (NSCLC). S. JANSSEN, L. KÄSMANN, V. RUDAT, D. RADES ( <i>Lübeck; Hannover, Germany; Al Khobar, Kingdom of Saudi Arabia</i> ) .....	825
Neoadjuvant Chemotherapy with Divided-dose Docetaxel, Cisplatin and Fluorouracil for Patients with Squamous Cell Carcinoma of the Esophagus. T. OJIMA, M. NAKAMORI, M. NAKAMURA, M. KATSUDA, K. HAYATA, T. KATO, J. KITADANI, H. TABATA, A. TAKEUCHI, M. IWAHASHI, H. YAMAUE ( <i>Wakayama, Japan</i> ) .....	829
Errata .....	835

Gene-expression Classifier in Papillary Thyroid Carcinoma: Validation and Application of a Classifier for Prognostication. S.C. LONDERO, M.L. JESPERSEN, A. KROGDAHL, L. BASTHOLT, J. OVERGAARD, S. SCHYTTE, C. GODBALLE, J. ALSNER: A study from The Danish Thyroid Cancer Group – DATHYRCA (Odense, Denmark) .....	749
High <i>NEK2</i> Expression Is a Predictor of Tumor Recurrence in Hepatocellular Carcinoma Patients After Hepatectomy. G.Y. WUBETU, Y. MORINE, H. TERAOKU, M. YOSHIKAWA, D. ISHIKAWA, S. YAMADA, T. IKEMOTO, Y. SAITO, S. IMURA, M. SHIMADA (Tokushima, Japan) .....	757
Influence of Local Recurrence and Distant Metastasis on Prognosis After Local Excision of Rectal Carcinoma. T. JUNGINGER, U. GOENNER, M. HITZLER, T.T. TRINH, A. LOLLERT, A. HEINTZ, D. WOLLSCHLAEGER, M. BLETTNER (Mainz, Germany) .....	763
Giant Cavernous Hepatic Hemangioma Diagnosed Incidentally in a Perimenopausal Obese Female with Endometrial Adenocarcinoma: A Case Report. T. BARA JR, S. GURZU, I. JUNG, M. MURESAN, J. SZEDERJESI, T. BARA (Tirgu-Mures, Romania) .....	769
The Role of TPS and TPA in the Diagnostics of Distant Metastases. R. KUCERA, O. TOPOLCAN, O. FIALA, J. KINKOROVA, V. TRESKA, I. ZEDNÍKOVÁ, D. SLOUKA, V. SIMANEK, M. SAFANDA, V. BABUSKA (Prague, Czech Republic) .....	773
Nipple-sparing Mastectomy in Patients with Preoperative Diagnosis of Non-invasive Breast Carcinoma. A Single-center Experience. M.I. AMABILE, M. MONTI, R. MEROLA, F. FRUSONE, V. D’ORAZI, V. PASTA (Rome, Italy) .....	779
Risk Factors Associated with Disease Recurrence in Patients with Stage III/IV Squamous Cell Carcinoma of the Oral Cavity Treated with Surgery and Postoperative Radiotherapy. A.R. NOBLE, J.F. GRESKOVICH, J. HAN, C.A. REDDY, T.I. NWIZU, M.F. KHAN, J. SCHARPF, D.J. ADELSTEIN, B.B. BURKEY, S.A. KOYFMAN (Cleveland, OH, USA) .....	785
Predictors of Benign Status in Liver Tumors Under 3 cm in Diameter Misdiagnosed as Hepatocellular Carcinoma. K. KIMURA, S. ITOH, T. KURIHARA, Y. YOSHIDA, H. WANG, N. HARIMOTO, A. NISHIE, K. SHIRABE, Y. ODA, Y. MAEHARA (Fukuoka, Japan) .....	793
Prognostic Significance of Preoperative Urine Cytology in Low-grade Non-muscle-invasive Bladder Cancer. K. KIYOSHIMA, M. AKITAKE, M. SHIOTA, A. TAKEUCHI, R. TAKAHASHI, J. INOKUCHI, K. TATSUGAMI, A. YOKOMIZO, M. ETO (Fukuoka, Japan) .....	799
Karnosky Performance Score and Radiation Dose Predict Survival of Patients Re-irradiated for a Locoregional Recurrence of Small Cell Lung Cancer. L. KÄSMANN, S. JANSSEN, S.E. SCHILD, D. RADES (Lübeck; Hannover, Germany; Scottsdale, AZ, USA) .....	803
Impact of Body Weight Loss on Recurrence After Curative Gastrectomy for Gastric Cancer. H. KUBO, S. KOMATSU, D. ICHIKAWA, T. KAWAGUCHI, T. KOSUGA, K. OKAMOTO, H. KONISHI, A. SHIOZAKI, H. FUJIWARA, E. OTSUJI (Kyoto, Japan) .....	807
The Usefulness of Diffusion MRI in Detection of Lymph Node Metastases of Colorectal Cancer. M. OGAWA, N. ICHIBA, M. WATANABE, K. YANAGA (Tokyo, Japan) .....	815
Orbital Apex Syndrome Caused by Invasive Aspergillosis as an Adverse Effect of Systemic Chemotherapy for Metastatic Colorectal Cancer: a Case Report. Y. MIYAMOTO, Y. SAKAMOTO, M. OHUCHI, R. TOKUNAGA, H. SHIGAKI, J. KURASHIGE, M. IWATSUKI, Y. BABA, N. YOSHIDA, M. WATANABE, H. BABA (Kumamoto; Tokyo, Japan) .....	821

L-Carnosine Prevents the Pro-cancerogenic Activity of Senescent Peritoneal Mesothelium Towards Ovarian Cancer Cells. J. MIKUŁA-PIETRASIK, K. KSIAŻEK ( <i>Poznań, Poland</i> ) .....	665
Sugar-carrying Polystyrenes Facilitate Harvesting of APCs from MLRs: Possible Application of Sugar-carrying Polystyrenes to Immunotherapy. A. IMAIZUMI, H. ONISHI, A. YAMASAKI, M. KAWAMOTO, T. MORISAKI, M. GOTO, M. IWAMA, T. AKAIKE, K. HASUMI ( <i>Tokyo; Fukuoka; Kanagawa, Japan</i> ) .....	673
High <i>PTPRQ</i> Expression and Its Relationship to Expression of <i>PTPRZ1</i> and the Presence of <i>KRAS</i> Mutations in Colorectal Cancer Tissues. I. LACZMANSKA, P. KARPINSKI, J. GIL, L. LACZMANSKI, M. BEBENEK, M.M. SASIADEK ( <i>Wroclaw, Poland</i> ) .....	677
Antiproliferative and Pro-apoptotic Activities of a Novel Resveratrol Prodrug Against Jurkat CD4+ T-Cells. K. GOLDHAHN, N. HANDLER, S. LOEBSCHE, K. SCHMETTERER, G. STEINER, B. KLOESCH, T. ERKER ( <i>Vienna, Austria</i> ) .....	683
Synergistic and Antagonistic AML Cell Type-specific Responses to 5-Aza-2-deoxycytidine and 1-h-D-Arabinofuranoside. A.A. ELMONEIM, E. HEUSTON, D.H. WAI, T. TRICHE, R.J. ARCECI ( <i>Sohag, Egypt; Baltimore, MD; Phoenix, AZ; Los Angeles, CA, USA; Madina, Kingdom of Saudi Arabia</i> ) .....	691
ER-Dependent Ca <sup>++</sup> -mediated Cytosolic ROS as an Effector for Induction of Mitochondrial Apoptotic and ATM-JNK Signal Pathways in Gallic Acid-treated Human Oral Cancer Cells. Y.-C. LU, M.-L. LIN, H.-L. SU, S.-S. CHEN ( <i>Taichung, Taiwan, ROC</i> ) .....	697
Apolipoprotein E Genotypes in Patients with Prostate Cancer. F. YENCILEK, S.G. YILMAZ, A. YILDIRIM, U. GORMUS, E.M. ALTINKILIC, A.B. DALAN, Y. BASTUG, S. TURKMEN, S. TURKAN, T. ISBIR ( <i>Istanbul; Kastamonu, Turkey</i> ) .....	707

### Clinical Studies

A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours. N. FAZIO, R. BUZZONI, E. BAUDIN, L. ANTONUZZO, R.A. HUBNER, H. LAHNER, W.W. DE HERDER, M. RADERER, A. TEULÉ, J. CAPDEVILA, S.K. LIBUTTI, M.H. KULKE, M. SHAH, D. DEY, S. TURRI, P. AIMONE, C. MASSACESI, C. VERSLYPE ( <i>Milan; Florence, Italy; Villejuif; Paris, France; Manchester, UK; Essen, Germany; Rotterdam, the Netherlands; Vienna, Austria; Barcelona, Spain; New York, NY; Boston, MA; Columbus, OH, USA; Hyderabad, India; Basel, Switzerland; Leuven, Belgium</i> ) .....	713
Hypoxia-regulated MicroRNAs in Gastroesophageal Cancer. M. WINTHER, J. ALSNER, B.S. SØRENSEN, C.F. WITTRUP, T. TRAMM, L. BAEKSGAARD, K. HOF LAND, E. HOLTVED, M. NORDSMARK ( <i>Aarhus; Copenhagen; Odense, Denmark</i> ) .....	721
Treatment Results of Radiotherapy Combined with Balloon-occluded Arterial Infusion Chemotherapy for Invasive Bladder Cancer. H. YOSHIOKA, T. SHIMBO, K. YOSHIDA, N. YOSHIKAWA, Y. UESUGI, K. YAMAMOTO, H. AZUMA, Y. NARUMI ( <i>Osaka, Japan</i> ) .....	731
Radiochemotherapy with Gemcitabine in Unresectable Extrahepatic Cholangiocarcinoma: Long-term Results of a Phase II Study. R. AUTORINO, G.C. MATTIUCCI, F. ARDITO, M. BALDUCCI, F. DEODATO, G. MACCHIA, G. MANTINI, V. PERRI, A. TRINGALI, M.A. GAMBACORTA, L. TAGLIAFERRI, F. GIULIANTE, A.G. MORGANTI, V. VALENTINI ( <i>Rome; Campobasso, Italy</i> ) .....	737
A Feasibility Study of Neoadjuvant XELOX Without Radiotherapy for Locally Advanced Lower Rectal Cancer. T. UEKI, T. MANABE, S. INOUE, J. IENAGA, N. YAMANAKA, T. EGAMI, M. ISHIKAWA, H. KONOMI, A. IKUBO, K. NAGAYOSHI, M. NAKAMURA, M. TANAKA ( <i>Fukuoka; Yamaguchi; Kitakyushu; Saga, Japan</i> ) .....	741

Taurine Attenuates Dimethylbenz[ <i>a</i> ]anthracene-induced Breast Tumorigenesis in Rats: A Plasma Metabolomic Study. Y. HE, Q.Q. LI, S.C. GUO ( <i>Nanning, PR China; Bethesda, MD, USA</i> ) .....	533
Intestinal Tumor Development in C57BL/6J-Apc <sup>Min/+</sup> Mice Expressing Human Sulphotransferases 1A1 and 1A2 After Oral Exposure to 2,5-Dimethylfuran. A.H. HØIE, C. SVENDSEN, T. RASMUSSEN, J. ALEXANDER, T. HUSØY ( <i>Oslo, Norway</i> ).....	545
Restoring Natural Killer Cell Cytotoxicity After Hyperthermia Alone or Combined with Radiotherapy. T. HIETANEN, M. KAPANEN, P.-L. KELLOKUMPU-LEHTINEN ( <i>Tampere, Finland</i> ) .....	555
HSV-1 Infection Modulates the Radioresponse of a HPV16-positive Head and Neck Cancer Cell Line. A. TURUNEN, V. HUKKANEN, J. KULMALA, S. SYRJANEN ( <i>Turku, Finland</i> ).....	565
Altered Micro-RNA Degradation Promotes Tumor Heterogeneity: A Result from Boolean Network Modeling. Y. WU, G.R.F. KRUEGER, G. WANG ( <i>Shenzhen, Guangdong, PR China; Houston, TX, USA</i> ) .....	575
$\alpha$ -Bisabolol Inhibits Invasiveness and Motility in Pancreatic Cancer Through KISS1R Activation. M. UNO, T. KOKURYO, Y. YOKOYAMA, T. SENGU, M. NAGINO ( <i>Nagoya, Japan</i> ) .....	583
Polyphosphate Derived from <i>Lactobacillus brevis</i> Inhibits Colon Cancer Progression Through Induction of Cell Apoptosis. A. SAKATANI, M. FUJIYA, N. UENO, S. KASHIMA, J. SASAJIMA, K. MORIICHI, K. IKUTA, H. TANABE, Y. KOHGO ( <i>Asahikawa, Hokkaido; Nasushiobara, Tochigi, Japan</i> ) .....	591
Polo-like Kinase Inhibitor Volasertib Exhibits Antitumor Activity and Synergy with Vincristine in Pediatric Malignancies. S. ABBOU, C. LANVERS-KAMINSKY, E. DAUDIGEOS-DUBUS, L. LE DRET, C. LAPLACE-BUILHE, J. MOLENAAR, G. VASSAL, B. GEOERGER; within the ITCC Biology and Preclinical Evaluation Committee ( <i>Villejuif, France; Muenster, Germany; Amsterdam, the Netherlands</i> ).....	599
Expression of Submaxillary Gland Androgen-regulated Protein 3A ( <i>SMR3A</i> ) in Adenoid Cystic Carcinoma of the Head and Neck. J. THIERAUF, J.A. VEIT, J. GRÜNOW, J. DÖSCHER, S. WEIBINGER, T. WHITESIDE, D. BEUTNER, P. PLINKERT, T.K. HOFFMANN, J. HESS ( <i>Ulm; Heidelberg; Köln, Germany; Pittsburgh, PA, USA</i> ).....	611
<i>PLAGL1</i> ( <i>ZAC1/LOT1</i> ) Expression in Clear Cell Renal Cell Carcinoma: Correlations with Disease Progression and Unfavorable Prognosis. J. GODLEWSKI, B.E. KRAZINSKI, A.E. KOWALCZYK, J. KIEWISZ, J. KIEZUN, P. KWIAKOWSKI, A. SLIWINSKA-JEWSIEWICKA, Z. MASLOWSKI, Z. KMIEC ( <i>Olsztyn; Gdansk, Poland</i> ) .....	617
Development of Stemness in Cancer Cell Lines Resistant to the Anticancer Effects of Zoledronic Acid. A. YOSHIYAMA, T. MORII, K. OHTSUKA, H. OHNISHI, T. TAJIMA, T. AOYAGI, K. MOCHIZUKI, K. SATOMI, S. ICHIMURA ( <i>Tokyo, Japan</i> ) .....	625
Sensitivity Profiles of Human Prostate Cancer Cell Lines to an 80 Kinase Inhibitor Panel. A.J. BURKE, H. ALI, E. O'CONNELL, F.J. SULLIVAN, S.A. GLYNN ( <i>Galway, Ireland</i> ) .....	633
Inhibitory Effects of the Four Main Theaflavin Derivatives Found in Black Tea on Ovarian Cancer Cells. Y. GAO, G.O. RANKIN, Y. TU, Y.C. CHEN ( <i>Hangzhou, PR China; Philippi; Huntington, WV, USA</i> ) .....	643
Hypoxic Conditions Promote Gemcitabine Sensitivity in a Pancreatic Cancer Stem Cell Line. A. IMAIZUMI, H. ONISHI, A. YAMASAKI, M. KAWAMOTO, M. UMEBAYASHI, T. MORISAKI, K. HASUMI ( <i>Tokyo; Fukuoka, Japan</i> ) .....	653
Loss of SFRP1 Expression Is Associated with Poor Prognosis in Hepatocellular Carcinoma. M. DAVAADORJ, S. IMURA, Y. SAITO, Y. MORINE, T. IKEMOTO, S. YAMADA, C. TAKASU, T. HIROKI, M. YOSHIKAWA, M. SHIMADA ( <i>Tokushima, Japan</i> ) .....	659